Sun Pharma gets USFDA nod for Generic Amphotericin B Liposome Injection

Published On 2021-12-17 05:39 GMT   |   Update On 2021-12-17 05:39 GMT

Mumbai: Sun Pharmaceutical Industries Limited has announced that one of its wholly-owned subsidiaries has received final approval from United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for generic Amphotericin B Liposome for Injection, 50 mg/vial Single-Dose Vial. The generic product approval is based on AmBisome Liposome for Injection,...

Login or Register to read the full article

Mumbai: Sun Pharmaceutical Industries Limited has announced that one of its wholly-owned subsidiaries has received final approval from United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for generic Amphotericin B Liposome for Injection, 50 mg/vial Single-Dose Vial.

The generic product approval is based on AmBisome Liposome for Injection, 50 mg/vial as a reference product.

"Sun Pharma has been granted Competitive Generic Therapy (CGT) designation by US FDA and being the first approved generic, is eligible for 180 days of CGT exclusivity for the product," the company said in a release.

As per October 2021 IQVIA Health data, AmBisome Liposome for Injection, 50mg/vial had annualized sales of approximately US$ 136 million in USA.

Read also: Sun Pharma gets CDSCO panel nod to Brinzolamide, Timolol Maleate, Potassium Sorbate FDC

Sun Pharma is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra. The company manufacture and market a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies. It includes generics, branded generics, specialty, complex or difficult to make technology-intensive products, over-the-counter (OTC), antiretrovirals (ARVs), Active Pharmaceutical Ingredients (APIs) and Intermediates. 

Read also: Sun Pharma gets CDSCO panel nod to Brinzolamide, Timolol Maleate, Potassium Sorbate FDC


Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News